This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: April 5, 2012
Last updated: August 21, 2012
Last verified: August 2012
Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.

Condition Intervention Phase
Healthy Drug: Fostamatinib Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The percent of absolute bioavailability (F) of R406 after oral administration of fostamatinib. [ Time Frame: Up to 96 hours post dose ]
  • Total radioactivity of [14C] R406 after an intravenous infusion of [14C]R406 in terms of AUC, AUC(0-t), Cmax, t1/2λz, MRT, CL, Vz. [ Time Frame: Up to 96 hours post dose ]
    AUC-Area under the plasma concentration time curve; AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration; Cmax - max plasma concentration; t½ λz-Terminal half-life; MRT- Mean residence time; CL - Total body clearance; Vz - Volume of distribution during the terminal phase

  • Pharmacokinetic (PK) profile of a single oral dose of fostamatinib and a radiolabelled intravenous micro tracer dose of [14C] R406. [ Time Frame: 0, 30min, 1h, 1h 30min, 1h 45min, 1h 50min, 1h 55min, 2, 2h 5min, 2h 10min, 2h 15min, 2h30min, 3, 3h 30min, 5h30min, 9h, 12h, 18h, 24h, 30h, 48h, 72h, 96h post-dose ]
    PK Parameters: AUC, AUC (0-t), Cmax, t½ λz and MRT

Secondary Outcome Measures:
  • Number of participants with Adverse Events. [ Time Frame: Up to Day 12 ]
  • Safety profile in terms of vital signs (blood pressure and pulse), clinical laboratory tests, ECGs and physical examination findings. [ Time Frame: Up to Day 12 ]

Enrollment: 37
Study Start Date: May 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fostamatinib 50 mg tablet Drug: Fostamatinib
Fostamatinib 50 mg tablet
Experimental: Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose Drug: Fostamatinib
Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose

Detailed Description:
A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers aged 18 to 55 years (inclusive), with a weight of at least 50 kg and a body mass index (BMI) between 18 and 30 kg/m2 (inclusive)
  • Male volunteers willing to use barrier contraception ie, condoms with spermicide, from the first day of the investigational product administration until 3 months after the last administration of the investigational product

Exclusion Criteria:

  • History of any clinically significant disease or disorder
  • History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of drug
  • Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day
  • Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results as judged by the Investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01598571

United Kingdom
Ruddington, Nottingham, United Kingdom
Sponsors and Collaborators
Study Director: Mark Layton, MD AstraZeneca, Alderley Park
Principal Investigator: Sharan Sidhu, MB CHB, BAO, MRCS Quotient Clinical Unit
  More Information

Responsible Party: AstraZeneca Identifier: NCT01598571     History of Changes
Other Study ID Numbers: D4300C00027
Study First Received: April 5, 2012
Last Updated: August 21, 2012

Keywords provided by AstraZeneca:
Phase 1
Healthy male volunteers
R406 plasma AUC and Cmax
R406 plasma AUC0-t
tmax processed this record on June 23, 2017